Antibody-mediated targeting of replication-competent retroviral vectors

Chien Kuo Tai, Christopher R. Logg, Jinha M. Park, W. French Anderson, Michael F. Press, Noriyuki Kasahara

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Replication-competent murine leukemia virus (MLV) vectors can be engineered to achieve high efficiency gene transfer to solid tumors in vivo and tumor-restricted replication, however their safety can be further enhanced by redirecting tropism of the virus envelope. We have therefore tested the targeting capability and replicative stability of ecotropic and amphotropic replication-competent retrovirus (RCR) vectors containing two tandem repeats from the immunoglobulin G-binding domain of Staphylococcal protein A inserted into the proline-rich "hinge" region of the envelope, which enables modular use of antibodies of various specificities for vector targeting. The modified envelopes were efficiently expressed and incorporated into virions, were capable of capturing monoclonal anti-HER2 antibodies, and mediated efficient binding of the virus-antibody complex to HER2-positive target cells. While infectivity was markedly reduced by pseudotyping with targeted envelopes alone, coexpression of wild-type envelope rescued efficient cellular entry. Both ecotropic and amphotropic RCR vector/anti-HER2 antibody complexes achieved significant enhancement of transduction on murine target cells overexpressing HER2, which could be competed by preincubation with excess free antibodies. Interestingly, HER2-expressing human breast cancer cells did not show enhancement of transduction despite efficient antibody-mediated cell surface binding, suggesting that target cell-specific parameters markedly affect the efficiency of post-binding entry processes. Serial replication of targeted vectors resulted in selection of Z domain deletion variants, but reduction of the overall size of the vector genome enhanced its stability. Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design.

Original languageEnglish (US)
Pages (from-to)789-802
Number of pages14
JournalHuman Gene Therapy
Volume14
Issue number8
DOIs
StatePublished - May 20 2003
Externally publishedYes

Fingerprint

Antibodies
Retroviridae
Anti-Idiotypic Antibodies
Virus Attachment
Genome Size
Murine Leukemia Viruses
Neoplasms
Tandem Repeat Sequences
Tropism
Antibody Specificity
Staphylococcal Protein A
Virus Replication
Proline
Virion
Immunoglobulin G
Monoclonal Antibodies
Breast Neoplasms
Viruses
Safety
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Antibody-mediated targeting of replication-competent retroviral vectors. / Tai, Chien Kuo; Logg, Christopher R.; Park, Jinha M.; Anderson, W. French; Press, Michael F.; Kasahara, Noriyuki.

In: Human Gene Therapy, Vol. 14, No. 8, 20.05.2003, p. 789-802.

Research output: Contribution to journalArticle

Tai, Chien Kuo ; Logg, Christopher R. ; Park, Jinha M. ; Anderson, W. French ; Press, Michael F. ; Kasahara, Noriyuki. / Antibody-mediated targeting of replication-competent retroviral vectors. In: Human Gene Therapy. 2003 ; Vol. 14, No. 8. pp. 789-802.
@article{99d915249d76472fbe8107790c201889,
title = "Antibody-mediated targeting of replication-competent retroviral vectors",
abstract = "Replication-competent murine leukemia virus (MLV) vectors can be engineered to achieve high efficiency gene transfer to solid tumors in vivo and tumor-restricted replication, however their safety can be further enhanced by redirecting tropism of the virus envelope. We have therefore tested the targeting capability and replicative stability of ecotropic and amphotropic replication-competent retrovirus (RCR) vectors containing two tandem repeats from the immunoglobulin G-binding domain of Staphylococcal protein A inserted into the proline-rich {"}hinge{"} region of the envelope, which enables modular use of antibodies of various specificities for vector targeting. The modified envelopes were efficiently expressed and incorporated into virions, were capable of capturing monoclonal anti-HER2 antibodies, and mediated efficient binding of the virus-antibody complex to HER2-positive target cells. While infectivity was markedly reduced by pseudotyping with targeted envelopes alone, coexpression of wild-type envelope rescued efficient cellular entry. Both ecotropic and amphotropic RCR vector/anti-HER2 antibody complexes achieved significant enhancement of transduction on murine target cells overexpressing HER2, which could be competed by preincubation with excess free antibodies. Interestingly, HER2-expressing human breast cancer cells did not show enhancement of transduction despite efficient antibody-mediated cell surface binding, suggesting that target cell-specific parameters markedly affect the efficiency of post-binding entry processes. Serial replication of targeted vectors resulted in selection of Z domain deletion variants, but reduction of the overall size of the vector genome enhanced its stability. Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design.",
author = "Tai, {Chien Kuo} and Logg, {Christopher R.} and Park, {Jinha M.} and Anderson, {W. French} and Press, {Michael F.} and Noriyuki Kasahara",
year = "2003",
month = "5",
day = "20",
doi = "10.1089/104303403765255174",
language = "English (US)",
volume = "14",
pages = "789--802",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Antibody-mediated targeting of replication-competent retroviral vectors

AU - Tai, Chien Kuo

AU - Logg, Christopher R.

AU - Park, Jinha M.

AU - Anderson, W. French

AU - Press, Michael F.

AU - Kasahara, Noriyuki

PY - 2003/5/20

Y1 - 2003/5/20

N2 - Replication-competent murine leukemia virus (MLV) vectors can be engineered to achieve high efficiency gene transfer to solid tumors in vivo and tumor-restricted replication, however their safety can be further enhanced by redirecting tropism of the virus envelope. We have therefore tested the targeting capability and replicative stability of ecotropic and amphotropic replication-competent retrovirus (RCR) vectors containing two tandem repeats from the immunoglobulin G-binding domain of Staphylococcal protein A inserted into the proline-rich "hinge" region of the envelope, which enables modular use of antibodies of various specificities for vector targeting. The modified envelopes were efficiently expressed and incorporated into virions, were capable of capturing monoclonal anti-HER2 antibodies, and mediated efficient binding of the virus-antibody complex to HER2-positive target cells. While infectivity was markedly reduced by pseudotyping with targeted envelopes alone, coexpression of wild-type envelope rescued efficient cellular entry. Both ecotropic and amphotropic RCR vector/anti-HER2 antibody complexes achieved significant enhancement of transduction on murine target cells overexpressing HER2, which could be competed by preincubation with excess free antibodies. Interestingly, HER2-expressing human breast cancer cells did not show enhancement of transduction despite efficient antibody-mediated cell surface binding, suggesting that target cell-specific parameters markedly affect the efficiency of post-binding entry processes. Serial replication of targeted vectors resulted in selection of Z domain deletion variants, but reduction of the overall size of the vector genome enhanced its stability. Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design.

AB - Replication-competent murine leukemia virus (MLV) vectors can be engineered to achieve high efficiency gene transfer to solid tumors in vivo and tumor-restricted replication, however their safety can be further enhanced by redirecting tropism of the virus envelope. We have therefore tested the targeting capability and replicative stability of ecotropic and amphotropic replication-competent retrovirus (RCR) vectors containing two tandem repeats from the immunoglobulin G-binding domain of Staphylococcal protein A inserted into the proline-rich "hinge" region of the envelope, which enables modular use of antibodies of various specificities for vector targeting. The modified envelopes were efficiently expressed and incorporated into virions, were capable of capturing monoclonal anti-HER2 antibodies, and mediated efficient binding of the virus-antibody complex to HER2-positive target cells. While infectivity was markedly reduced by pseudotyping with targeted envelopes alone, coexpression of wild-type envelope rescued efficient cellular entry. Both ecotropic and amphotropic RCR vector/anti-HER2 antibody complexes achieved significant enhancement of transduction on murine target cells overexpressing HER2, which could be competed by preincubation with excess free antibodies. Interestingly, HER2-expressing human breast cancer cells did not show enhancement of transduction despite efficient antibody-mediated cell surface binding, suggesting that target cell-specific parameters markedly affect the efficiency of post-binding entry processes. Serial replication of targeted vectors resulted in selection of Z domain deletion variants, but reduction of the overall size of the vector genome enhanced its stability. Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design.

UR - http://www.scopus.com/inward/record.url?scp=0038021046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038021046&partnerID=8YFLogxK

U2 - 10.1089/104303403765255174

DO - 10.1089/104303403765255174

M3 - Article

VL - 14

SP - 789

EP - 802

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 8

ER -